Healthcare is ever evolving in response to challenges brought on by the modern times: cancer and heart disease, but also aging, obesity and overpopulation, to name just a few. Innovative new solutions are needed, solutions that decrease time-to-diagnosis, lower the barrier to entry for some patients and offer more personalized healthcare.
Biosensors offer exactly that. They are small medical devices that measure the concentration of biomarkers in a bodily fluid, such as saliva or blood plasma. These biomarkers are indicators of disease and allow for an estimation of the patient’s physiological state. Because of their size, they offer unprecedented flexibility, allowing measurement in the hospital, at the general practitioner’s office and, most importantly, at home.
T.E.S.T. is a multi-disciplinary team that competes in annual international student competition SensUs, that challenges teams from all over the world to push the boundaries of what biosensors are capable of. This way, T.E.S.T. intends to empower the patients and revolutionize healthcare.
The 2017 team
The second T.E.S.T. team developed a biosensor for NT-proBNP, a biomarker for heart failure, a disease afflicting 1% of all Europeans. Heart failure damages patients’ mobility and forces frequent hospital trips. T.E.S.T. contributed to the treatment of heart failure by adapting
an opto-magnetic cluster assay developed by Adrea Ranzoni of Menno Prins’ Molecular Biosensing for Medical Diagnostics research group (TU/e): with this principle, they booked spectacular results, winning three of the four prizes of the SensUs event.